Answers are grounded in this paper and cite their sources.
Systematically characterizing antibody-drug conjugates (ADCs) is essential for understanding their therapeutic properties, guiding molecular design, and supporting clinical development. Recently, the expanding clinical landscape of ADCs has generated extensive information on target antigens, therapeutic indications, and clinical trial pipelines, providing a valuable foundation for informing ADC development strategies. Moreover, ADMET profiles are critical for understanding the in vivo disposition, efficacy, and safety of ADCs. Integrating these accumulating clinical and pharmacological data is therefore necessary to enrich the evidence available for ADC development. In this study, ADCdb was updated to provide (i) detailed clinical landscape information for 542 ADCs, together with >3000 manually curated clinical trials from registries across nine registries and clinical trial platforms; (ii) >4000 ADMET profiles, including quantitative pharmacokinetic parameters and descriptive annotations supported by relevant references; and (iii) expanded pharmacological information and biological activity data comprising 13 088 ADC entries and 24 821 activity records, as well as ADC-specific functional annotations for 389 ADCs. Interactive visualization tools and antigen- and disease-centered search modules further enable systematic exploration of ADC composition, therapeutic indications, and clinical development. ADCdb 2.0 is expected to serve as a valuable resource for rational optimization of ADCs, and is accessible at https://idrblab.org/adcdb/.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: